A Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product

• Sponsor: isRed Pharma & Biotech Research Corporation (Industry)
• Overall Status: Unknown status
• CT.gov ID: NCT02444507
• Collaborator: Yung Shin Pharmaceutical Ind. Co., Ltd. (Other)
• Enrollment: 14
• Location: 1
• Arms: 2
• Duration (Months): 2
• Patients Per Site Per Month: 7

Study Details

Study Description

Brief Summary

To assess the bioequivalence of esomeprazole of the TEST product vs. the REFERENCE product in healthy volunteers who reside in Taiwan.

Condition or Disease	Intervention/Treatment	Phase
Healthy Adult Subjects	Drug: Nexium powder for injection and infusion 40 mg; Drug: Esomelone Powder for Solution for Injection / Infusion 40 mg	Phase 4

Detailed Description

This study is designed to assess the bioequivalence of esomeprazole of the TEST product vs. the REFERENCE product in healthy volunteers who reside in Taiwan. Bioequivalence will be assumed if the 90% confidence interval of the AUC0-t, AUC0-inf and Cmax ratio are within the 80-125% interval for log-transformed values.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 14 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Single (Participant)
• Official Title: A Randomized, Two-Way Crossover, Single-Dose Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product (Nexium Powder for Injection and Infusion 40 mg) in Healthy Adult Subjects
• Study Start Date: Apr 1, 2015
• Anticipated Primary Completion Date: May 1, 2015
• Anticipated Study Completion Date: Jun 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Reference Drug: Nexium Name: Nexium powder for injection and infusion 40 mg, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.	Drug: Nexium powder for injection and infusion 40 mg; Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
Active Comparator: Test Drug: Esomelone Name: Esomelone Powder for Solution for Injection / Infusion 40 mg Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.	Drug: Esomelone Powder for Solution for Injection / Infusion 40 mg; Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.

Outcome Measures

Primary Outcome Measures

1. Bioequivalence will be assumed if the 90% confidence interval of the AUC0-t, AUC0-inf and Cmax ratio are within the 80-125% interval for log-transformed values. [Sampling Schedule: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10 and 12 hr]

   The calculation of the respective pharmacokinetic will be based upon the reported concentrations and sampling times.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 20 Years to 40 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. Healthy adult, aged between 20 to 40 years old.

2. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests, chest x-ray and electrocardiogram.

3. The normal range of the body mass index should between 18.5 and 25.

4. Normal laboratory determinations results including: SGOT (AST), SGPT (ALT), albumin, glucose, creatinine, uric acid, cholesterol, TG, γ-GT, alkaline phosphatase, total bilirubin, BUN, HBsAg, Anti-HCV and Anti-HIV test.

5. Normal hematology results including: hemoglobin, hematocrit, WBC count with differential, RBC count and platelet count.

6. Normal urinalysis results including: glucose, protein, RBC, WBC, epith, casts and bacteria.

7. Female subject who is:

• using adequate contraception since last menstruation and no plan for conception during the study.

• non-lactating.

• has negative pregnancy test (urine) within 14 days prior to the study.

1. Informed consent form signed.

Exclusion Criteria:

1. A history of drug or alcohol abuse during the past 24 weeks.

2. Sensitivity to analogous drug.

3. A clinically significant illness (such as significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis, melaena or gastric ulcer) within the past 4 weeks.

4. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoetic, neurological, pulmonary or gastrointestinal pathology within the past 4 weeks.

5. Planed vaccination during the time course of the study.

6. Participation of any clinical investigation during the last 60 days.

7. Regular use of any medication during the last 4 weeks.

8. Single use of any medication during the last 2 weeks.

9. Blood donation of more than 250 mL within the past 12 weeks.

10. Individuals are judged by the investigator or co-investigator to be undesirable as subjects.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Taichung Veterans General Hospital	Taichung City		Taiwan	40705

Sponsors and Collaborators

• isRed Pharma & Biotech Research Corporation
• Yung Shin Pharmaceutical Ind. Co., Ltd.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: isRed Pharma & Biotech Research Corporation
• ClinicalTrials.gov Identifier: NCT02444507
• Other Study ID Numbers: YSP RFH3002-01
• First Posted: May 14, 2015
• Last Update Posted: May 14, 2015
• Last Verified: May 1, 2015

• Additional relevant MeSH terms: Esomeprazole

Study Results

No Results Posted as of May 14, 2015